HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc.(NASDAQ: NRXP), announced plans to acquire a network of interventional psychiatry clinics, focusing on ketamine treatments. The acquisition and financing agreements, valued at $30 million, are backed by a qualified lender. The company signed a non-binding Term Sheet for five operational clinics in the Western United States, generating over $10 million in annual revenue. The clinics will focus on treating conditions like suicidal depression, treatment-resistant depression (TRD), and PTSD. HOPE Therapeutics aims to create a unifie…